GLP-1 receptor agonists (GLP-1RAs), medications commonly used for diabetes and weight loss, may improve lung function in adults with cystic…
Articles by Patricia Inácio, PhD
The Cystic Fibrosis Foundation has awarded University of Michigan researchers $900,000 over two years to advance new treatments for cystic fibrosis (CF)…
The Cystic Fibrosis Foundation is investing up to $7.3 million in Ride Therapeutics to develop nonviral carriers of genetic therapies intended to…
Most adults with cystic fibrosis (CF) surveyed at a U.S. care center had never received genetic counseling, and many…
A Phase 2a clinical trial testing RCT2100, Recode Therapeutics’ investigational inhaled mRNA therapy for cystic fibrosis (CF), is fully…
The Cystic Fibrosis Foundation is funding a new research project that aims to develop a cell-based strategy…
One year of treatment with Kaftrio lowered levels of certain immune cells implicated in inflammation, led to fewer pulmonary…
People with cystic fibrosis (CF) in Canada are a step closer to gaining public access to Alyftrek, a…
Blackstone Life Sciences is investing $250 million in Anagram Therapeutics to advance ANG003, an oral enzyme replacement therapy…
Children with cystic fibrosis who carry two Trikafta-responsive mutations are significantly more likely to reach normal or near-normal…